Thanks for these details! Edit: it's still bugging me that this doesn't describe the utility of the additional clinical screen more specifically. Is the point

Thanks for these details! Edit: it's still bugging me that this doesn't describe the utility of the additional clinical screen more specifically. Is the point that even if false positives are rare, the treat path is informed by full sequence data? Would love additional insight. These details are important to me because I think low cost tests can fill a public health niche that "only the most comprehensive test" strategies leave underserved. Any progress in those areas is likely to meet resistance, because it could bite into the margins of folks offering broader packages. So I am really interested in how both scientific and popular articles portray the tradeoffs.